Immunotherapy Regimen Approved for Recurrent Ovarian Cancer

(MedPage Today) — The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency announced on Tuesday.
Approval stipulates use of the combination, with or without bevacizumab, in adults…

Source link : https://www.medpagetoday.com/hematologyoncology/ovariancancer/119831

Author :

Publish date : 2026-02-10 22:32:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Immunotherapy Regimen Approved for Recurrent Ovarian Cancer

Gene Therapy Shows Signs of Delayed Progression in Fatal Neurodegenerative Disease

FDA Clears AI Program for Lung Cancer Screening

Related Posts

One Question Can Jumpstart Urinary Incontinence Referrals

‘Diet Stacking’ May Complicate Managing GI Disorders

Newborn marsupials seen crawling to mother’s pouch for the first time

More Evidence Supports Exercise for Depression, Anxiety

FDA Clears AI Program for Lung Cancer Screening

Gene Therapy Shows Signs of Delayed Progression in Fatal Neurodegenerative Disease

One Question Can Jumpstart Urinary Incontinence Referrals

‘Diet Stacking’ May Complicate Managing GI Disorders

Newborn marsupials seen crawling to mother’s pouch for the first time

More Evidence Supports Exercise for Depression, Anxiety

FDA Clears AI Program for Lung Cancer Screening

Immunotherapy Regimen Approved for Recurrent Ovarian Cancer

Gene Therapy Shows Signs of Delayed Progression in Fatal Neurodegenerative Disease

Cancer in Canada: Progress Made, but Challenges Remain

Categories

Archives